Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Safety and Efficacy Study in Acute Ischaemic Stroke
A Phase II, Multi-centre, Two-part Study to Evaluate the Safety and Efficacy of Study Drug in Acute Ischaemic Stroke.
Status: Enrolling
Updated:  12/9/2015
Division of Neuro-Ophthalmology, Virginia Commonwealth University
mi
from
Richmond, VA
Safety and Efficacy Study in Acute Ischaemic Stroke
A Phase II, Multi-centre, Two-part Study to Evaluate the Safety and Efficacy of Study Drug in Acute Ischaemic Stroke.
Status: Enrolling
Updated: 12/9/2015
Division of Neuro-Ophthalmology, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety and Efficacy Study in Acute Ischaemic Stroke
A Phase II, Multi-centre, Two-part Study to Evaluate the Safety and Efficacy of Study Drug in Acute Ischaemic Stroke.
Status: Enrolling
Updated:  12/9/2015
Gordon & Leslie Diamond Health Care Centre
mi
from
Vancouver,
Safety and Efficacy Study in Acute Ischaemic Stroke
A Phase II, Multi-centre, Two-part Study to Evaluate the Safety and Efficacy of Study Drug in Acute Ischaemic Stroke.
Status: Enrolling
Updated: 12/9/2015
Gordon & Leslie Diamond Health Care Centre
mi
from
Vancouver,
Click here to add this to my saved trials
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)
A Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Repeat Oral Doses of V81444 in Volunteers With Attention Deficit / Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/9/2015
Vince and Associates Clinical Research
mi
from
Kansas City, KA
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)
A Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Repeat Oral Doses of V81444 in Volunteers With Attention Deficit / Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/9/2015
Vince and Associates Clinical Research
mi
from
Kansas City, KA
Click here to add this to my saved trials
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension
Status: Enrolling
Updated:  12/10/2015
Beth Israel Deaconess Medical Center (Harvard)
mi
from
Boston, MA
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension
Status: Enrolling
Updated: 12/10/2015
Beth Israel Deaconess Medical Center (Harvard)
mi
from
Boston, MA
Click here to add this to my saved trials
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension
Status: Enrolling
Updated:  12/10/2015
New York University
mi
from
New York, NY
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension
Status: Enrolling
Updated: 12/10/2015
New York University
mi
from
New York, NY
Click here to add this to my saved trials
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension
Status: Enrolling
Updated:  12/10/2015
Vanderbilt University
mi
from
Nashville, TN
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension
Status: Enrolling
Updated: 12/10/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension
Status: Enrolling
Updated:  12/10/2015
The Mayo Clinic
mi
from
Rochester, MN
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension
Status: Enrolling
Updated: 12/10/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Albuquerque, NM
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Berkeley, CA
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Berkeley, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Fresno, CA
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Newport Beach, CA
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Aurora, CO
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Tampa, FL
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Vero Beach, FL
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Vero Beach, FL
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Northbrook, IL
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Northbrook, IL
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Farmington Hills, MI
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Minneapolis, MN
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Raleigh, NC
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Cincinnati, OH
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Uniontown, OH
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Uniontown, OH
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Cordova, TN
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Cordova, TN
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
Knoxville, TN
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
mi
from
San Antonio, TX
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
mi
from
Calgary,
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
mi
from
Calgary,
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 10192
mi
from
Cullman, AL
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 10192
mi
from
Cullman, AL
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 1327
mi
from
Gilbert, AZ
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 1327
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 34
mi
from
Phoenix, AZ
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 34
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 36
mi
from
Fresno, CA
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 36
mi
from
Fresno, CA
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 10147
mi
from
Long Beach, CA
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 10147
mi
from
Long Beach, CA
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 10136
mi
from
Newport Beach, CA
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 10136
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 10665
mi
from
Oceanside, CA
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 10665
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 1315
mi
from
Centennial, CO
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 1315
mi
from
Centennial, CO
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 10715
mi
from
Maitland, FL
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 10715
mi
from
Maitland, FL
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 1347
mi
from
Pompano Beach, FL
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 1347
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 017
mi
from
St. Petersburg, FL
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 017
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site
mi
from
Tampa, FL
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 1303
mi
from
Northbrook, IL
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 1303
mi
from
Northbrook, IL
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 47
mi
from
Indianapolis, IN
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 47
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 1370
mi
from
Baltimore, MD
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 1370
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 08
mi
from
Great Falls, MT
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 08
mi
from
Great Falls, MT
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 11136
mi
from
Henderson, NV
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 11136
mi
from
Henderson, NV
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 10188
mi
from
Patchogue, NY
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 10188
mi
from
Patchogue, NY
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 38
mi
from
Plainview, NY
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 38
mi
from
Plainview, NY
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 1356
mi
from
Charlotte, NC
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 1356
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site
mi
from
Raleigh, NC
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site
mi
from
Winston-Salem, NC
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 10309
mi
from
Bellevue, OH
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 10309
mi
from
Bellevue, OH
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site
mi
from
Columbus, OH
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Teva Investigational Site 1313
mi
from
Dayton, OH
Safety and Tolerability of Glatiramer Acetate
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Teva Investigational Site 1313
mi
from
Dayton, OH
Click here to add this to my saved trials